Resmed in the news
Medical devices for chronic diseases
Tamtam found 20 recent articles about Resmed.
- ResMed CEO Michael J. Farrell Vests 48,136 Performance-Based Shares in November 2026
ResMed CEO Michael J. Farrell vested 48,136 performance-based shares and surrendered 28,180 shares for tax withholding.
- Form 4 RESMED INC For: Nov 19 Filed by: Drexler Karen
Karen Drexler, a director at Resmed, filed a Form 4 detailing Restricted Stock Units that vest by November 2027 or the next annual meeting.
- Form 4 RESMED INC For: Nov 19 Filed by: De Witte Jan
A director at ResMed Inc. received Restricted Stock Units that will vest by November 2027.
- Is This the Right Time to Hold Resmed Stock in Your Portfolio?
Resmed is expanding its connected sleep device platforms globally and in international markets, but faces intense competition and macroeconomic cost pressures.
- Form 4 RESMED INC For: Nov 19 Filed by: Leong Justin
Justin Leong, Chief Product Officer at ResMed Inc., had performance-based restricted stock units vest on November 19, 2026, as certified by the compensation committee.
- How Resmed Inc. (RMD) Affects Rotational Strategy Timing
Resmed Inc. (RMD) is at a critical technical juncture, testing resistance with a high-risk short opportunity and mixed sentiment.
- ResMed director Ronald Taylor retires from board
ResMed director Ronald Taylor retired from the board at the November 18, 2026 annual meeting, not seeking re-election.
- Three years of results could put ResMed (RMD) executives at twice their FY2027 stock award targets.
ResMed executives are poised to double their FY2027 stock award targets based on three years of financial results.
- Is At Home Sleep Testing Altering The Investment Case For ResMed (RMD)?
ResMed's acquisition of VirtuOx aims to strengthen its virtual sleep clinic offerings, integrating at-home testing and monitoring to enhance its digital sleep and respiratory ecosystem.
- ResMed Board Reduced to Ten Directors After Ronald Taylor Retirement at November 2026 Annual Meeting
ResMed reduced its board to ten directors after Ronald Taylor's retirement and introduced a new performance-based stock unit award structure for executive compensation.
- Why Are ResMed (ASX:RMD), Commonwealth Bank and BHP Blue Chips in Focus?
The article discusses the latest updates from three Australian blue-chip companies: ResMed's quarterly results and outlook, Commonwealth Bank's lending growth, and BHP's resources operations.
- FDA puts gastric implants on device shortages list, adds Resmed product discontinuation
The FDA updated its device shortages and discontinued devices list, adding gastric implants and removing angiographic syringes, and also added Resmed's Astral ventilators to the discontinued list due to supply constraints.
- ResMed director Jan De Witte sells $101,673 of common stock By Investing.com
A ResMed director sold company stock, while the company reported strong Q1 2027 earnings and received mixed analyst ratings.
- ResMed (RMD) director plans to sell 429 shares acquired through stock vesting.
A director at ResMed is planning to sell 429 shares obtained from stock vesting.
- ResMed Inc. (ASX:RMD): How Do FY27 First-Quarter Results Compare With Its Annual Outlook?
ResMed Inc. reported a 6% increase in first-quarter FY27 revenue, reaching $1.4 billion, while maintaining its full-year revenue and earnings guidance.
- ResMed (ASX:RMD) vs Pro Medicus (ASX:PME): Health Rally Twist
Australian healthcare shares have recovered significantly since June, with ResMed showing strong fundamentals and Pro Medicus facing valuation scrutiny.
- ResMed (ASX:RMD) Margin Expansion Puts the Spotlight Back on Profit
ResMed reported increased revenue and gross margin expansion in its September quarter, driven by strong mask sales and strategic focus after selling its MatrixCare business.
- Resmed (ASX:RMD): What Do September-Quarter Earnings and FY27 Guidance Show?
Resmed reported a 6% increase in Q1 FY27 revenue to USD 1.415 billion and a 23% rise in diluted earnings per share to USD 2.92, while reiterating its full-year guidance.
- ResMed Share Price: A$35.20, Up 0.69% Nov 16
ResMed's share price rose by 0.69% to A$35.20 on November 16, 2026, marking a five-session gain, while technical indicators show an uptrend despite softened momentum and thin trading volume.
- ResMed (RMD), Why Is The Sleep Health Leader Back In Focus?
ResMed's stock is considered undervalued by analysts at $239.53, despite recent cooling in share price performance, with future growth expected from expanded diagnosis and treatment funnels.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Resmed?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies